FCR-HM40DB-100μg / 询价
FCR-HM40DB-500μg / 询价
FCR-HM40DB-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Biotinylated Human FcRH5/FcRL5 Domain Protein
Recombinant Biotinylated Human FcRH5/FcRL5 Domain Protein is expressed from HEK293 with His tag and Avi tag at the N-terminus.It contains Val745-Thr850 [Accession | Q96RD9-1].
The protein has a predicted MW of 14.0 kDa. Due to glycosylation, the protein migrates to 25-40 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human FcRH5 Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human FcRH5 Domain is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human FcRH5 Domain, His-Avi Tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-FcRH5 Antibody, hFc Tag with the EC50 of 5.8ng/ml determined by ELISA. (QC Test)
Loaded Anti-FcRH5 Antibody, hFc Tag on ProA-Biosensor can bind Biotinylated Human FcRH5 Domain, His-Avi Tag with an affinity constant of 1.10 nM as determined in BLI assay (Gator® Prime).
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2
(1) Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163.MCT-12-0087.
